PhRMA CEO on PBM exploitation: ‘Now collect more in rebates, discounts, and fees than the total price of drugs’

Stephen J. Ubl, President and CEO of PhRMA - PhRMA
Stephen J. Ubl, President and CEO of PhRMA - PhRMA
0Comments

Stephen J. Ubl, President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), said that American leaders should address the role of intermediaries in the drug supply chain. He noted that these intermediaries now capture more in rebates, discounts, and fees than the total price of drugs. The statement was made in an op-ed.

“American leaders can start by tackling the bloated middle of the drug supply chain,” said J. Ubl. “Middlemen who neither invent nor administer medicines to patients now collect more in rebates, discounts, and fees than the total price of drugs in many other countries.”

Pharmacy benefit managers (PBMs) act as third-party administrators for prescription drug programs. They negotiate with manufacturers to secure discounts and rebates, manage pharmacy networks, and process claims for insurers and employers. Their role also includes medication therapy management and mail-order pharmacy services, making them influential intermediaries in the U.S. drug supply chain.

A 2025 Federal Trade Commission report revealed that the three largest PBMs—Caremark Rx, Express Scripts, and OptumRx—generated over $7.3 billion in revenue from significant markups on specialty generic drugs between 2017 and 2022. This practice often involves charging health plans more than what pharmacies are reimbursed, a method known as spread pricing, which allows PBMs to retain the difference as profit.

According to Save Community Pharmacies, during the first half of 2024, Pennsylvania experienced the closure of 140 pharmacies. Nearly a third of counties in the state now have fewer than 10 pharmacies. These closures have been attributed to inadequate reimbursement rates from PBMs, creating financial strain for independent pharmacies.

Ubl has served as President and CEO of PhRMA since 2015, where he leads advocacy efforts for the U.S. biopharmaceutical industry and represents member companies on public policy issues. Before joining PhRMA, he was president and CEO of AdvaMed, the world’s largest medical technology association.



Related

David Metcalf, U.S. Attorney for the Eastern District of Pennslyvania

Savani Group owners and associate convicted of racketeering conspiracy in Philadelphia

Three members associated with the Savani Group were convicted for running an extensive racketeering scheme involving visa fraud, healthcare fraud, money laundering, tax evasion, mail fraud, FDCA violations, among other charges in Philadelphia on Mar. 9. Authorities say millions were stolen from government programs through these schemes.

David Metcalf, U.S. Attorney for the Eastern District of Pennslyvania

Par Funding pleads guilty to conspiracy in investor fraud scheme

Par Funding has pleaded guilty to conspiracy charges tied to defrauding investors out of hundreds of millions of dollars. Several top executives have also been convicted or sentenced as part of this wide-ranging scheme.

Lt. Gov. Austin Davis

Pennsylvania sees 13.2% drop in corporation net income taxes collections in 2024

Out of the $55.2 billion in total tax revenue collected by Pennsylvania in 2024, $5 billion came from corporation net income taxes, representing a decrease from the previous year, when the total was $5.7 billion, according to the U.S. Census Bureau’s Annual Survey of State Government Tax Collections (STC).

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Keystone Today.